



Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/598,700
				Filing Date	
				First Named Inventor	RAY, Partho S., et al.
				Group Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	88870.007

FOREIGN PATENT DOCUMENTS							
Exam. Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant	Publication Date (MM-YYYY)	Trans.
		Office	Number	Kind Code (if known)			
		WO	2003/087138	A2	Rigel Pharmaceuticals, Inc.	10-2003	
		WO	1994/005813	A1	Mochida Pharmaceutical Co.	03-1994	

NON-PATENT LITERATURE DOCUMENTS			
Exam. Initials	Cite No.	Include: Name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Trans.
		IMBERT, I., et al., "Hepatitis C virus IRES efficiency is unaffected by the genomic RNA 3'NTR even in the presence of viral structural or non-structural proteins" <i>Journal of General Virology</i> , 2003, Vol. 84, pp. 1549-1557.	
		TALLET-LOPEZ, B., et al. "Antisense oligonucleotides targeted to the domain III <sub>d</sub> of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation" <i>Nucleic Acids Research</i> , 2003, Vol. 31, No. 2, pp. 734-742.	

Examiner Signature	/Sean McGarry/	Date Considered	05/07/2008
--------------------	----------------	-----------------	------------